Drugs get a human face
In the not-too-distant future, our genes will determine the type of drug and its dosage.Pharmacogenomics offers the promise of tailor-made drugs and gives a way into the therapy that targets specific ailments.Katya Naidu explores the finer aspects of this new form of therapy.
Pfizer’s Norvasc reduces cardiovascular events
A study by Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) show that patients with high blood pressure and additional cardiovascular risk factors, who received Pfizer’s calcium channel blocker Norvasc (marketed in India as Amlogard), experienced reductions in cardiovascular death, all-cause mortality and other cardiovascular events, including heart attacks and strokes. The results were published in the The Lancet.
Multi-component drug delivery system: An emerging trend
Swarnlata Saraf and K Dashora give an overview of multi-component therapy, which is a way of increasing drug efficacy when a single drug fails.